Form 8-K - Current report:
SEC Accession No. 0001104659-20-123073
Filing Date
2020-11-09
Accepted
2020-11-09 16:18:16
Documents
14
Period of Report
2020-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2035471d1_form8k.htm   iXBRL 8-K 25718
2 EXHIBIT 99.1 tm2035471d1_ex99-1.htm EX-99.1 98147
6 GRAPHIC image_001.jpg GRAPHIC 4848
  Complete submission text file 0001104659-20-123073.txt   316946

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mrkr-20201109.xsd EX-101.SCH 3189
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrkr-20201109_lab.xml EX-101.LAB 34591
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrkr-20201109_pre.xml EX-101.PRE 22712
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2035471d1_form8k_htm.xml XML 3615
Mailing Address 3200 SOUTHWEST FREEWAY SUITE 2250 HOUSTON TX 77027
Business Address 3200 SOUTHWEST FREEWAY SUITE 2250 HOUSTON TX 77027 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

EIN.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37939 | Film No.: 201297931
SIC: 2834 Pharmaceutical Preparations